In patients with 10% to 20% risk of FN, G-CSF must be indicated in patients with age more than 65 years, hepatic or renal dysfunction, persistent neutropenia, coexisting morbidities or prior episodes of FN. The gene discussed is CSF3; the disease is Decreased total neutrophil count.